Saudi Arabia Cracks Down on Imported Chicken Broth over Banned Dyes
The Saudi Food and Drug Authority (SFDA) has issued a critical warning against consuming Maragatty chicken broth, an Egyptian-imported product, after detecting prohibited synthetic dyes that threaten public health. The agency emphasized the urgency of halting its distribution due to the presence of Dimethyl Yellow, Sudan I, and Sudan IV—chemicals banned in food globally for their potential carcinogenic effects. Recall Ordered Amid Growing Safety Concerns
In a swift response, the SFDA ordered an immediate recall of all 480-gram containers of Maragatty broth with a best-before date of 1 November, 2026. Transitional measures, such as clear signage in retail outlets and social media alerts, aim to ensure consumers are informed. The authority urges households to discard the product safely and avoid further use, prioritizing long-term health over convenience.
#الغذاء_والدواء
تحذّر من منتج مرقة الدجاج للعلامة التجارية (Maragatty) لاحتوائه على ألوان صناعية محظورة قد تشكل خطرًا صحيًا على المستهلك؛ وتم اتخاذ الإجراءات النظامية تجاه الشركة المستوردة وسحب المنتج من الأسواق. pic.twitter.com/itkugQYDTx
— إمارة منطقة مكة المكرمة (@makkahregion) February 28, 2025
Offenders face fines up to SR10 million, imprisonment for up to a decade, or both—deterrents designed to uphold rigorous compliance 10. The SFDA reaffirmed its zero-tolerance policy, stating, 'No compromise exists when public health is at stake.' SFDA's Dedication to Food Safety
To foster transparency, the SFDA has activated its unified contact center to receive consumer reports on unsafe products. By promoting community awareness, the agency aims to strengthen trust in Saudi Arabia's regulatory frameworks. As part of its commitment, the SFDA will continue monitoring markets and enforcing penalties to safeguard consumer rights.
Through proactive measures like this recall, the SFDA reinforces its role as a guardian of public health. By leveraging clear communication, strict enforcement, and public engagement, the Kingdom remains a regional leader in food safety innovation and consumer protection.
Short link :
Post Views: 1
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Saudi Gazette
04-06-2025
- Saudi Gazette
SFDA elected to Management Committee of MedDRA, the 6th global regulatory body
Saudi Gazette report RIYADH — In a move that highlights Saudi Arabia's growing prominence in global pharmaceutical governance, the Saudi Food and Drug Authority (SFDA) has been officially elected to the Management Committee of the Medical Dictionary for Regulatory Activities (MedDRA). The authority has thus become the sixth regulatory authority worldwide to join this prestigious global medical body. This election marks a pivotal milestone for both Saudi Arabia and the international scientific community, reflecting global confidence in the SFDA's regulatory excellence and the Kingdom's strategic role in advancing international harmonization in drug safety and medical product oversight. MedDRA, developed by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), is a globally recognized standard for coding and analyzing safety data across the lifecycle of pharmaceutical and biopharmaceutical products. It plays a central role in regulatory communication, post-market surveillance, clinical trial reporting, and signal detection. SFDA's election to the MedDRA Steering committee was confirmed during the ICH Management Committee meeting held in Madrid, Spain, from May 11–12, 2025. With this appointment, SFDA joins a group of regulators, including the European Commission, U.S. FDA, UK MHRA, Health Canada, Japan's MHLW and PMDA, alongside the World Health Organization (WHO), which participates as an observer. This strategic appointment reaffirms SFDA's active leadership within ICH working groups, particularly in the areas of medical terminology and pharmacovigilance. Among its most impactful contributions is the linguistic and technical leadership demonstrated in the translation and validation of over 20,000 MedDRA terms into Arabic—a landmark initiative completed between May and October 2022. This achievement significantly facilitates the implementation of MedDRA across Arabic-speaking regions and enhances inclusive pharmacovigilance throughout the MENA region. For CEOs, scientific leaders, and policymakers, this development signals new opportunities to align regulatory frameworks, accelerate clinical development across the region, and enhance data interoperability. SFDA's presence on the MedDRA Steering Committee is not merely symbolic—it serves as a strategic platform for integrating global safety data, advancing regulatory innovation, and sharing best practices. As Saudi Arabia continues to lead in biopharma localization, digital health, and AI-driven pharmacovigilance, SFDA's role in shaping the evolution of MedDRA is set to reinforce the Kingdom's position at the forefront of global health regulation.
Saudi Gazette
30-05-2025
- Saudi Gazette
SFDA CEO reviews Hajj readiness and AI-powered safety protocols in Makkah
Saudi Gazette report MAKKAH — As part of Saudi Arabia's preparations to ensure the safety and well-being of pilgrims during Hajj 2025, Dr. Hisham Aljadhey, Chief Executive Officer of the Saudi Food and Drug Authority (SFDA), conducted a field tour of SFDA operations in Makkah. The visit focused on evaluating the readiness of regulatory services and the implementation of the Authority's operational plans for the pilgrimage season. Dr. Aljadhey emphasized to SFDA inspectors and monitors the critical importance of safeguarding the food and medicine consumed by pilgrims. He commended the dedication of teams deployed across all sites under SFDA's jurisdiction, describing their work as a national duty and an honor in service to the guests of the Holy Mosque. The tour included a visit to the SFDA's Hajj Operations Center, where Aljadhey reviewed real-time coordination with other government agencies, inspection monitoring procedures, and support systems in place for field teams. Officials demonstrated the use of advanced tools, including body-worn cameras, smart sensors, and digital inspection systems integrated with artificial intelligence, which help enhance regulatory efficiency and ensure the safety of products distributed during Hajj. Aljadhey also inspected SFDA's base in the regulatory zone of the Holy Sites area, which oversees surveillance of food factories and storage facilities. Field teams presented procedures for collecting food samples and sending them for lab testing to verify safety standards, using digital platforms that support traceability and rapid data analysis. The tour continued with a visit to Mina's Emergency Hospital, where Dr. Aljadhey met with Dr. Abdullah Al-Algwizani, CEO of the Public Health Authority 'Weqaya.' Discussions focused on collaborative efforts between the two entities to strengthen public health protections for pilgrims. At the National Health Emergency and Crisis Management Center, Aljadhey was briefed on integrated efforts by various health and regulatory authorities. He stressed the significance of coordination in managing health emergencies and enhancing regulatory effectiveness throughout the Hajj season. The SFDA teams showcased cutting-edge analytical and AI tools deployed to bolster public health oversight and ensure that all food and drug products meet stringent safety requirements, reinforcing the Authority's role in supporting a safe and seamless pilgrimage.
Saudi Gazette
20-05-2025
- Saudi Gazette
SFDA launches awareness campaign for safe use of home medical devices
Saudi Gazette report RIYADH — The Saudi Food and Drug Authority (SFDA) has launched a digital awareness campaign to educate the public on the safe and proper use of medical devices and supplies intended for home use. This campaign aligns with its ongoing commitment to public health and is a key component of its fourth strategic plan. By leveraging digital and social media platforms, the SFDA aims to effectively reach diverse segments of the community, providing essential awareness messages and practical guidance to enhance health safety in the home environment. In a press statement, the SFDA emphasized the importance of purchasing home medical devices from a licensed supplying facility that offers warranty and after-sales services, including necessary maintenance. It also highlighted the need to verify that the specific medical device has the required licenses and a valid marketing authorization certificate. Given the wide range of available options and specifications, the SFDA advised consulting a qualified healthcare specialist to select the most appropriate device type for the individual's medical condition. It also underscored the need to review the instructions for proper use and care, and to obtain any necessary training before purchase. The authority also highlighted that the general safe use guidelines include ensuring that instructions for use are available in both Arabic and English, retaining the purchase receipt; keeping devices out of children's and pets' reach to prevent tampering that could affect settings or electrical wiring, and adhering to recommended calibration schedules and periodic maintenance. The SFDA urged the public to report any issues or incidents related to home medical devices or supplies through the National Center for Medical Devices Reporting at or by calling the unified call number 19999.
